ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Clinical outcomes of 577-nm subthreshold micropulse laser therapy in chronic central serous chorioretinopathy: influence of retinal pigment epithelium alterations and baseline OCT characteristics.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the 6-month clinical outcomes of 577-nm subthreshold micropulse laser treatment (SMPLT) in patients with chronic central serous chorioretinopathy (cCSCR) and to identify factors associated with complete resolution of subretinal fluid (CRSF).
methodsThis retrospective cross-sectional study included patients with cCSCR treated with 577-nm SMPLT using a 15% duty cycle. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), subretinal fluid height (SRFH), subfoveal choroidal thickness (SFCT), choroidal vascularity index (CVI), and outer nuclear layer thickness (ONLT) were evaluated at baseline and at 1, 3, and 6 months after treatment. Factors influencing CRSF were analyzed.
resultsThirty-five eyes of 35 patients were included. BCVA improved significantly at all follow-up visits compared with baseline (all p < 0.001). CFT and SRFH decreased significantly at 1, 3, and 6 months after treatment (all p < 0.001). SFCT showed significant reduction at 1 and 6 months (p = 0.001 and p = 0.018), whereas no significant changes were observed in CVI or ONLT. CRSF was achieved in 22.9% of eyes at 1 month, 48.6% at 3 months, and 60% at 6 months. Higher complete resolution rates were observed in eyes without retinal pigment epithelium (RPE) alterations (75% vs. 57.1%). Female sex was associated with lower complete resolution rates, while higher baseline CFT and SRFH and CVI were associated with CRSF.
conclusions577-nm SMPLT using a 15% duty cycle was associated with significant functional and anatomical improvement in cCSCR. Treatment before the development of RPE alterations may be associated with more favorable anatomical outcomes.
Indexed as
Identifiers
42397590What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.